According to the Guojin Securities Research Report, the BD boom in innovative drugs is rising, leading the world in cutting-edge tracks such as ADC and dual antibodies. Combining review efficiency and cost advantages, Chinese pharmaceutical companies are deeply embedded in the global industrial chain. TOP15 MNC invests about 200 billion US dollars in external cooperation every year. This year, it has reached 2003 billion dollars, and a boom in mergers and acquisitions has been established. With the expansion of domestic back-end pipelines, medical insurance negotiations, and the expansion of the basic drug catalogue, the industry has entered a golden period of performance fulfillment. The valuation of Hong Kong stocks has bottomed out, foreign holdings have been cut to the bottom, the allocation of capital from the south has increased, global pharmaceutical sentiment has picked up, and the allocation window for high-quality targets has arrived.

According to the Guojin Securities Research Report, the BD boom in innovative drugs is rising, leading the world in cutting-edge tracks such as ADC and dual antibodies. Combining review efficiency and cost advantages, Chinese pharmaceutical companies are deeply embedded in the global industrial chain. TOP15 MNC invests about 200 billion US dollars in external cooperation every year. This year, it has reached 2003 billion dollars, and a boom in mergers and acquisitions has been established. With the expansion of domestic back-end pipelines, medical insurance negotiations, and the expansion of the basic drug catalogue, the industry has entered a golden period of performance fulfillment. The valuation of Hong Kong stocks has bottomed out, foreign holdings have been cut to the bottom, the allocation of capital from the south has increased, global pharmaceutical sentiment has picked up, and the allocation window for high-quality targets has arrived.